ImmunityBio 10-Q: Q3 Revenue $48.7M, $334.3M Cash, Going-Concern Warning
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio's Q3 10-Q shows revenue up 53% to $48.7 million and $334.3 million in cash, but includes an explicit going-concern warning and a $1.05 billion nine-month loss that is mostly non-cash remeasurement of its related-party note and warrants.
Key Events · Earnings and Guidance · IBRX
-
Q3 Revenue Up 53% to $48.7M
Net product revenue reached $48.7 million versus $31.8 million a year earlier; nine-month revenue was $143.6 million, up 92% from $74.7 million.
-
Going-Concern Warning Restated
Management states substantial doubt exists about the ability to continue as a going concern without additional funding, relying on cash, product sales, equity issuance and loans from affiliates to fund the next 12 months.
-
$1.05B Loss Is Mostly Non-Cash
The nine-month net loss of $1,047.8 million includes a $393.2 million non-cash change in fair value of the related-party convertible note and a $355.4 million non-cash change in fair value of warrant liabilities — mark-to-market moves tied to the share price, not cash outflows or new dilution.
-
Balance Sheet: $334.3M Cash vs $1.75B Liabilities
Cash, equivalents and marketable securities totaled $334.3 million at September 30, 2026, against total liabilities of $1,754.8 million and a stockholders' deficit of $1,145.4 million; the $480.0 million related-party note matures December 2027.
Analysis · IBRX · Life Sciences
Revenue growth is real — Q3 net product revenue of $48.7 million is up 53% and the nine-month total of $143.6 million is up 92% — but the company still burns cash and says substantial doubt exists about its ability to continue as a going concern without more funding. The $1.05 billion nine-month net loss is mostly accounting: $393.2 million from remeasuring the related-party convertible note and $355.4 million from remeasuring warrant liabilities, both non-cash and both driven by a higher share price, not by operations. What actually matters is the balance sheet: $334.3 million of cash and securities against $1.75 billion of liabilities, a $480.0 million related-party note due December 2027, and a revenue interest obligation to Oberland that now stands at $426.3 million. The ATM has $319.9 million left and warrants keep getting exercised for cash, so the funding question is manageable near term — but it is still being answered by selling stock, not by the P&L.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBRX was trading at $7.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.